Lexicon Pharmaceuticals, Inc. (LXRX)
1.65
+0.05
(+3.12%)
USD |
NASDAQ |
Oct 15, 16:00
1.645
0.00 (0.00%)
After-Hours: 20:00
Lexicon Pharmaceuticals Cash from Operations (TTM) : -64.99M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -64.99M |
| March 31, 2026 | -38.80M |
| December 31, 2025 | -67.85M |
| September 30, 2025 | -73.42M |
| June 30, 2025 | -103.20M |
| March 31, 2025 | -168.74M |
| December 31, 2024 | -180.09M |
| September 30, 2024 | -207.84M |
| June 30, 2024 | -195.84M |
| March 31, 2024 | -185.41M |
| December 31, 2023 | -161.90M |
| September 30, 2023 | -132.92M |
| June 30, 2023 | -110.74M |
| March 31, 2023 | -97.04M |
| December 31, 2022 | -88.85M |
| September 30, 2022 | -90.11M |
| June 30, 2022 | -87.82M |
| March 31, 2022 | -85.28M |
| December 31, 2021 | -87.02M |
| September 30, 2021 | -98.43M |
| June 30, 2021 | -121.66M |
| March 31, 2021 | -146.07M |
| December 31, 2020 | -142.97M |
| September 30, 2020 | -133.10M |
| June 30, 2020 | 97.98M |
| Date | Value |
|---|---|
| March 31, 2020 | 117.37M |
| December 31, 2019 | 113.81M |
| September 30, 2019 | 111.05M |
| June 30, 2019 | -101.83M |
| March 31, 2019 | -127.45M |
| December 31, 2018 | -148.61M |
| September 30, 2018 | -155.19M |
| June 30, 2018 | -166.97M |
| March 31, 2018 | -146.67M |
| December 31, 2017 | -185.39M |
| September 30, 2017 | -200.47M |
| June 30, 2017 | -201.73M |
| March 31, 2017 | -217.38M |
| December 31, 2016 | -175.63M |
| September 30, 2016 | 139.09M |
| June 30, 2016 | 148.82M |
| March 31, 2016 | 164.52M |
| December 31, 2015 | 184.78M |
| September 30, 2015 | -85.61M |
| June 30, 2015 | -81.31M |
| March 31, 2015 | -68.79M |
| December 31, 2014 | -75.62M |
| September 30, 2014 | -92.90M |
| June 30, 2014 | -95.65M |
| March 31, 2014 | -97.13M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Bristol Myers Squibb Co. | 12.78B |
| ANI Pharmaceuticals, Inc. | 189.47M |
| Corcept Therapeutics, Inc. | 109.70M |
| Veru, Inc. | -26.04M |
| Johnson & Johnson | -- |